Clinical Study of Ophthalmic Arterial Infusion Chemotherapy Combined with Intravenous Chemotherapy in the Treatment of Children with Retinoblastoma
Objective:To investigate the clinical efficacy of ocular arterial infusion chemotherapy(IAC)combined with intravenous chemotherapy(IVC)in the treatment of children with retinoblastoma(RB).Methods:A total of 92 patients(113 eyes)with RB in the hospital from January 2019 to December 2021 were randomly divided into group A(46 patients,58 eyes)and group B(46 patients,55 eyes).Group B was treated with IAC combined with local treatment,and group A was treated with IAC combined with IVC.Eye protection rate,recurrence rate,metastasis rate,1-year survival rate,complication rate,and tumor marker levels[neuron-specific enolase(NSE)and glycoprotein antigen 153(CA153)]before and after chemotherapy were compared between the two groups.Results:There were no significant difference in eye preservation rate,metastasis rate and 1-year survival rate between 2 groups(x2=0.021,0.261,0;P＞0.05).The recurrence rate of group A was lower than that of group B,with statistically significant difference(x2=3.265,P＜0.05).After 3 cycles of chemotherapy,the serum NSE and CA153 levels in group A were lower than those in group B(t=3.470,2.920;P＜0.05).Conclusion:Compared with IAC alone,IAC combined with IVC can effectively reduce the recurrence rate and serum levels of NSE and CA153 in RB children,but the incidence of myosuppression complications is higher.
万方数据
维普
